一名接受每日剂量沙利度胺治疗的点状内层脉络膜病变患者脉络膜新生血管膜复发。
Recurrence of a choroidal neovascular membrane in a patient with punctate inner choroidopathy treated with daily doses of thalidomide.
作者信息
Ip M, Gorin M B
机构信息
Department of Ophthalmology, University of Pittsburgh School of Medicine, PA, USA.
出版信息
Am J Ophthalmol. 1996 Oct;122(4):594-5. doi: 10.1016/s0002-9394(14)72131-2.
PURPOSE
To determine whether thalidomide therapy can prevent a recurrence of a choroidal neovascular membrane in a patient with punctate inner choroidopathy.
METHODS
Case report. In a 38-year-old woman with bilateral punctate inner choroidopathy, thalidomide therapy was initiated three days after laser photocoagulation of a choroidal neovascular membrane.
RESULTS
The patient had a recurrence of the choroidal neovascular membrane eight months after the start of thalidomide therapy.
CONCLUSIONS
The failure of thalidomide to prevent a recurrence of a choroidal neovascular membrane in this patient suggests that this medication may have only a limited benefit in preventing recurrences of choroidal neovascular membranes.
目的
确定沙利度胺治疗能否预防点状内层脉络膜病变患者脉络膜新生血管膜复发。
方法
病例报告。一名38岁双侧点状内层脉络膜病变女性患者，在脉络膜新生血管膜激光光凝治疗三天后开始沙利度胺治疗。
结果
沙利度胺治疗开始八个月后，患者脉络膜新生血管膜复发。
结论
沙利度胺未能预防该患者脉络膜新生血管膜复发，提示该药物在预防脉络膜新生血管膜复发方面可能仅有有限益处。
Zotero 插件